During the corresponding time, Si Bone Inc recorded a revenue increase by 17.16 % year on year, sequentially revenue grew by 7.83 %. While revenue at the Si Bone Inc 's corporate clients
Si Bone Inc's Comment on Sales, Marketing and Customers
The company serves a customer base of over 12,000 U.S. physicians, including nearly 7,500 orthopedic and neurological surgeons and approximately 4,500 interventional spine physicians performing advanced spinal procedures. Its U.S. direct sales organization comprises 89 territory sales managers, 83 clinical specialists, and 320 third-party sales agents as of December 31, 2025. Internationally, the sales force includes 11 directly employed sales representatives and 28 third-party sales agents covering 38 countries. The company focuses on physicians specializing in spinal surgery and pain management, emphasizing emerging technologies and markets. It conducts targeted marketing, education, and outreach to increase awareness of sacroiliac joint disorders and minimally invasive surgical treatments among lower back pain sufferers. The company collaborates with physicians in product development to meet the needs of its physician customers and patients. Competitors and market participants mentioned in filings include Alphatec Holding Inc., Aurora Spine Corporation, Globus Medical, Inc., Medtronic plc, and Tenon Medical, Inc.
SI-BONE, Inc., a leading medical device company focusing on musculoskeletal disorders of the sacropelvic anatomy, has recently received FDA 510(k) clearance for its improved iFuse Bedrock Granite Implant System. This new system features a smaller 9.5 mm diameter, making it more versatile for use in various anatomical conditions. Additionally, the clearance now includes an expanded indication for pediatric patients and an expanded application that covers the S1 trajectory as well.The iFuse Bedrock Granite Implant System, when placed across the sacroiliac (SI) joint, provides sacroiliac fusion and sacropelvic fixation. This implant acts as a foundational element for multi-segment spinal fusion, offering more c...
Si Bone Inc’s Comment on Sales, Marketing and Customers
The company serves a customer base of over 12,000 U.S. physicians, including nearly 7,500 orthopedic and neurological surgeons and approximately 4,500 interventional spine physicians performing advanced spinal procedures. Its U.S. direct sales organization comprises 89 territory sales managers, 83 clinical specialists, and 320 third-party sales agents as of December 31, 2025. Internationally, the sales force includes 11 directly employed sales representatives and 28 third-party sales agents covering 38 countries. The company focuses on physicians specializing in spinal surgery and pain management, emphasizing emerging technologies and markets. It conducts targeted marketing, education, and outreach to increase awareness of sacroiliac joint disorders and minimally invasive surgical treatments among lower back pain sufferers. The company collaborates with physicians in product development to meet the needs of its physician customers and patients. Competitors and market participants mentioned in filings include Alphatec Holding Inc., Aurora Spine Corporation, Globus Medical, Inc., Medtronic plc, and Tenon Medical, Inc.
Sources:
Si bone inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Si bone inc’s corporate clients.
For your research, we’ve provided 9 tables on Si bone inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
183.07 %